Annovis Bio (ANVS) Stock Forecast, Price Target & Predictions

ANVS Stock Forecast

Annovis Bio stock forecast is as follows: an average price target of $25.67 (represents a 278.06% upside from ANVS’s last price of $6.79) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

ANVS Price Target

The average price target for Annovis Bio (ANVS) is $25.67 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $21.00. This represents a potential 278.06% upside from ANVS's last price of $6.79.

ANVS Analyst Ratings

Buy

According to 4 Wall Street analysts, Annovis Bio's rating consensus is 'Buy'. The analyst rating breakdown for ANVS stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Annovis Bio Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 16, 2024	Raghuram Selvaraju	H.C. Wainwright	-	-	240.14%	341.83%
Aug 13, 2024	Jason Kolbert	EF Hutton	-	-	166.84%	209.28%
Apr 30, 2024	Sumant Kulkarni	Canaccord Genuity	-	-	257.14%	282.92%

Row per page

Go to

The latest Annovis Bio stock forecast, released on Oct 16, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $30.00, which represents a 240.14% increase from the stock price at the time of the forecast ($8.82), and a 341.83% increase from ANVS last price ($6.79).

Annovis Bio Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	3
Avg Price Target	-	$30.00	$25.67
Last Closing Price	$6.79	$6.79	$6.79
Upside/Downside	-100.00%	341.83%	278.06%

In the current month, the average price target of Annovis Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Annovis Bio's last price of $6.79. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 01, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 03, 2024	Canaccord Genuity	Buy	Buy	Hold
Aug 13, 2024	EF Hutton		Buy	Initialise
Jul 11, 2024	H.C. Wainwright	Buy	Buy	Hold
Jul 02, 2024	Rodman & Renshaw	Buy	Buy	Hold
Jun 04, 2024	Rodman & Renshaw		Buy	Initialise

Row per page

Go to

Annovis Bio's last stock rating was published by H.C. Wainwright on Oct 01, 2024. The company gave ANVS a "Buy" rating, the same as its previous rate.

Annovis Bio Financial Forecast

Annovis Bio Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$12.12M	$11.44M	$11.21M	$10.98M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	$12.12M	$11.44M	$11.21M	$10.98M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	$12.12M	$11.44M	$11.21M	$10.98M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Annovis Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ANVS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Annovis Bio EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict ANVS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Annovis Bio's previous annual EBITDA (undefined) of $NaN.

Annovis Bio Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$285.47K	$363.32K	$456.75K	$355.54K	$-2.02M	$-1.82M	$-1.69M	$-5.51M	$-2.06M	$-1.86M	$-1.73M	$-1.82M	$-6.25M	$-5.45M	$-5.02M	$-3.80M	$-4.20M	$-8.86M	$-7.10M
High Forecast	$285.47K	$363.32K	$456.75K	$355.54K	$-2.02M	$-1.82M	$-1.69M	$-5.51M	$-2.06M	$-1.86M	$-1.73M	$-1.82M	$-6.25M	$-5.45M	$-5.02M	$-3.80M	$-4.20M	$-8.86M	$-7.10M
Low Forecast	$285.47K	$363.32K	$456.75K	$355.54K	$-2.02M	$-1.82M	$-1.69M	$-5.51M	$-2.06M	$-1.86M	$-1.73M	$-1.82M	$-6.25M	$-5.45M	$-5.02M	$-3.80M	$-4.20M	$-8.86M	$-7.10M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Annovis Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ANVS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Annovis Bio SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
High Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Annovis Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ANVS last annual SG&A of $NaN (undefined).

Annovis Bio EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	1	1	1	1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$0.02	$0.03	$0.04	$0.03	$-0.16	$-0.14	$-0.13	$-0.42	$-0.16	$-0.14	$-0.13	$-0.14	$-0.48	$-0.42	$-0.39	$-0.29	$-0.32	$-0.68	$-0.63
High Forecast	$0.02	$0.03	$0.04	$0.03	$-0.16	$-0.14	$-0.13	$-0.42	$-0.16	$-0.14	$-0.13	$-0.14	$-0.48	$-0.42	$-0.39	$-0.29	$-0.32	$-0.68	$-0.63
Low Forecast	$0.02	$0.03	$0.04	$0.03	$-0.16	$-0.14	$-0.13	$-0.42	$-0.16	$-0.14	$-0.13	$-0.14	$-0.48	$-0.42	$-0.39	$-0.29	$-0.32	$-0.68	$-0.63
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Annovis Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ANVS previous annual EPS of $NaN (undefined).

Annovis Bio Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INAB	IN8bio	-	-	4275.00%	Buy
RVPH	Reviva Pharmaceuticals	-	-	706.45%	Buy
NVAX	Novavax	-	-	531.84%	Buy
INZY	Inozyme Pharma	-	-	445.35%	Buy
CUE	Cue Biopharma	-	-	320.39%	Buy
ANVS	Annovis Bio	-	-	278.06%	Buy
IMNM	Immunome	-	-	221.97%	Buy
ABOS	Acumen Pharmaceuticals	-	-	203.03%	Buy
DAWN	Day One Biopharmaceuticals	-	-	190.85%	Buy
IOVA	Iovance Biotherapeutics	-	-	154.85%	Buy
TERN	Terns Pharmaceuticals	-	-	149.56%	Buy
ANIX	Anixa Biosciences	-	-	145.10%	Buy
MCRB	Seres Therapeutics	-	-	71.23%	Buy
AXSM	Axsome Therapeutics	-	-	24.68%	Buy
AVXL	Anavex Life Sciences	-	-	21.95%	Buy
GRCL	Gracell Bio	-	-	-41.46%	Buy

ANVS Forecast FAQ

Is Annovis Bio a good buy?

Yes, according to 4 Wall Street analysts, Annovis Bio (ANVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of ANVS's total ratings.

What is ANVS's price target?

Annovis Bio (ANVS) average price target is $25.67 with a range of $21 to $30, implying a 278.06% from its last price of $6.79. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Annovis Bio stock go up soon?

According to Wall Street analysts' prediction for ANVS stock, the company can go up by 278.06% (from the last price of $6.79 to the average price target of $25.67), up by 341.83% based on the highest stock price target, and up by 209.28% based on the lowest stock price target.

Can Annovis Bio stock reach $10?

ANVS's average twelve months analyst stock price target of $25.67 supports the claim that Annovis Bio can reach $10 in the near future.

What are Annovis Bio's analysts' financial forecasts?

Annovis Bio's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-11.05M (high $-11.05M, low $-11.05M), average SG&A $0 (high $0, low $0), and average EPS is $-0.852 (high $-0.852, low $-0.852). ANVS's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $45.74M (high $45.74M, low $45.74M), average EBITDA is $0 (high $0, low $0), average net income is $1.46M (high $1.46M, low $1.46M), average SG&A $0 (high $0, low $0), and average EPS is $0.113 (high $0.113, low $0.113).